Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.

Rico-Fontalvo J, Daza-Arnedo R, Elbert A, Correa-Rotter R, Dina-Batlle E, Lorca-Herrera E, de Moraes TP, Sánchez-Polo V, Builes-Montaño CE

Diabetes therapy : research, treatment and education of diabetes and related disorders18 Mar 2026Cited by 2 (Europe PMC)

PMID41848820PMCIDPMC13103125DOI10.1007/s13300-026-01854-8PepBankPUB-41848820

Read at source PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

6 results from studies that gave the peptide. 6 results from people.

01HumanSystematic reviewEfficacy outcome
In a systematic scoping review of adults with type 2 diabetes and/or overweight or obesity, with or without CKD, randomized evidence supported semaglutide reductions in composite kidney outcomes.
In plain wordsIn adults with type 2 diabetes and/or overweight or obesity, with or without CKD, the review reported fewer composite kidney outcomes with semaglutide.
Peptide
Semaglutide
Outcome
DecreaseComposite kidney outcomes
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Randomized evidence supports renal benefits for semaglutide, dulaglutide, and liraglutide, including reductions in composite kidney outcomes and slower eGFR decline.
3 context sentences(design, population, supporting numbers)
Summary · context
This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD.
Summary · context
Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025.
Summary · context
Eligible studies included phase 2-4 randomized controlled trials (RCTs), post hoc RCT analyses, and comparative observational studies reporting kidney outcomes.
Report a problemFND-4184882001
02HumanSystematic reviewEfficacy outcome
In a systematic scoping review of adults with type 2 diabetes and/or overweight or obesity, with or without CKD, randomized evidence supported slower eGFR decline with semaglutide.
In plain wordsIn adults with type 2 diabetes and/or overweight or obesity, with or without CKD, the review reported slower eGFR decline with semaglutide.
Peptide
Semaglutide
Outcome
DecreaseeGFR decline
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Randomized evidence supports renal benefits for semaglutide, dulaglutide, and liraglutide, including reductions in composite kidney outcomes and slower eGFR decline.
3 context sentences(design, population, supporting numbers)
Summary · context
This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD.
Summary · context
Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025.
Summary · context
Eligible studies included phase 2-4 randomized controlled trials (RCTs), post hoc RCT analyses, and comparative observational studies reporting kidney outcomes.
Report a problemFND-4184882002
03HumanSystematic reviewEfficacy outcome
In a systematic scoping review of adults with type 2 diabetes and/or overweight or obesity, with or without CKD, randomized evidence supported liraglutide reductions in composite kidney outcomes.
In plain wordsIn adults with type 2 diabetes and/or overweight or obesity, with or without CKD, the review reported fewer composite kidney outcomes with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseComposite kidney outcomes
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Randomized evidence supports renal benefits for semaglutide, dulaglutide, and liraglutide, including reductions in composite kidney outcomes and slower eGFR decline.
3 context sentences(design, population, supporting numbers)
Summary · context
This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD.
Summary · context
Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025.
Summary · context
Eligible studies included phase 2-4 randomized controlled trials (RCTs), post hoc RCT analyses, and comparative observational studies reporting kidney outcomes.
Report a problemFND-4184882003
04HumanSystematic reviewEfficacy outcome
In a systematic scoping review of adults with type 2 diabetes and/or overweight or obesity, with or without CKD, randomized evidence supported slower eGFR decline with liraglutide.
In plain wordsIn adults with type 2 diabetes and/or overweight or obesity, with or without CKD, the review reported slower eGFR decline with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseeGFR decline
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Randomized evidence supports renal benefits for semaglutide, dulaglutide, and liraglutide, including reductions in composite kidney outcomes and slower eGFR decline.
3 context sentences(design, population, supporting numbers)
Summary · context
This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD.
Summary · context
Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025.
Summary · context
Eligible studies included phase 2-4 randomized controlled trials (RCTs), post hoc RCT analyses, and comparative observational studies reporting kidney outcomes.
Report a problemFND-4184882004
05HumanSystematic reviewEfficacy outcome
In a systematic scoping review of adults with type 2 diabetes and/or overweight or obesity, with or without CKD, tirzepatide reduced albuminuria compared with insulin glargine.
In plain wordsIn adults with diabetes and/or overweight or obesity, with or without CKD, the review found less albuminuria with tirzepatide than insulin glargine.
Peptide
Tirzepatide
Outcome
DecreaseAlbuminuria
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide demonstrated consistent albuminuria reductions and attenuation of eGFR decline compared with insulin glargine.
3 context sentences(design, population, supporting numbers)
Summary · context
This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD.
Summary · context
Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025.
Summary · context
Eligible studies included phase 2-4 randomized controlled trials (RCTs), post hoc RCT analyses, and comparative observational studies reporting kidney outcomes.
Report a problemFND-4184882005
06HumanSystematic reviewEfficacy outcome
In a systematic scoping review of adults with type 2 diabetes and/or overweight or obesity, with or without CKD, tirzepatide attenuated eGFR decline compared with insulin glargine.
In plain wordsIn adults with diabetes and/or overweight or obesity, with or without CKD, the review found slower eGFR decline with tirzepatide than insulin glargine.
Peptide
Tirzepatide
Outcome
DecreaseeGFR decline
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide demonstrated consistent albuminuria reductions and attenuation of eGFR decline compared with insulin glargine.
3 context sentences(design, population, supporting numbers)
Summary · context
This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD.
Summary · context
Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025.
Summary · context
Eligible studies included phase 2-4 randomized controlled trials (RCTs), post hoc RCT analyses, and comparative observational studies reporting kidney outcomes.
Report a problemFND-4184882006

Studies that did not test the peptide alone3

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

07HumanNot a test of Liraglutide aloneSystematic reviewOther
Across agents including liraglutide, the review reported renal benefits partly independent of glycemic and weight effects.
In plain wordsIn adults with diabetes and/or overweight or obesity, pooled GLP-1-based therapies showed renal benefits partly independent of blood sugar and weight effects.
Peptide
Liraglutide
Outcome
Not applicableRenal benefits independent of glycemic and weight effects
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Across agents, renal benefits were partly independent of glycemic and weight effects.
4 context sentences(design, population, supporting numbers)
Summary · context
This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD.
Summary · context
Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025.
Summary · context
Randomized evidence supports renal benefits for semaglutide, dulaglutide, and liraglutide, including reductions in composite kidney outcomes and slower eGFR decline.
Summary · context
Tirzepatide demonstrated consistent albuminuria reductions and attenuation of eGFR decline compared with insulin glargine.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4184882007
08HumanNot a test of Semaglutide aloneSystematic reviewOther
Across agents including semaglutide, the review reported renal benefits partly independent of glycemic and weight effects.
In plain wordsIn adults with diabetes and/or overweight or obesity, pooled GLP-1-based therapies showed renal benefits partly independent of blood sugar and weight effects.
Peptide
Semaglutide
Outcome
Not applicableRenal benefits independent of glycemic and weight effects
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Across agents, renal benefits were partly independent of glycemic and weight effects.
4 context sentences(design, population, supporting numbers)
Summary · context
This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD.
Summary · context
Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025.
Summary · context
Randomized evidence supports renal benefits for semaglutide, dulaglutide, and liraglutide, including reductions in composite kidney outcomes and slower eGFR decline.
Summary · context
Tirzepatide demonstrated consistent albuminuria reductions and attenuation of eGFR decline compared with insulin glargine.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4184882008
09HumanNot a test of Tirzepatide aloneSystematic reviewOther
Across agents including tirzepatide, the review reported renal benefits partly independent of glycemic and weight effects.
In plain wordsIn adults with diabetes and/or overweight or obesity, pooled GLP-1-based therapies showed renal benefits partly independent of blood sugar and weight effects.
Peptide
Tirzepatide
Outcome
Not applicableRenal benefits independent of glycemic and weight effects
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Across agents, renal benefits were partly independent of glycemic and weight effects.
4 context sentences(design, population, supporting numbers)
Summary · context
This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD.
Summary · context
Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025.
Summary · context
Randomized evidence supports renal benefits for semaglutide, dulaglutide, and liraglutide, including reductions in composite kidney outcomes and slower eGFR decline.
Summary · context
Tirzepatide demonstrated consistent albuminuria reductions and attenuation of eGFR decline compared with insulin glargine.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4184882009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 5Current
27 Oct 2026, 16:32 UTC
Study data updated · source update from Europe PMC
Version 4
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.

Summary

Results from this study9

Studies that did not test the peptide alone3

Version history

Subjects

Publication types

Keywords